


# INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY 2021

OF HIV,  
HEPATITIS  
AND OTHER  
ANTIVIRAL  
DRUGS



VIRTUAL WORKSHOP  
20 - 22 SEPTEMBER 2021

## ORGANIZING COMMITTEE



**Marta Boffito**  
MD, PhD, FRCP

Chelsea and Westminster  
Hospital, NHS Foundaton  
Trust, United Kingdom



**Andrea Calcagno**  
MD, DTM&H

University of Torino, Italy



**Jennifer Kiser**  
PharmD

University of Colorado Health  
Sciences Center, USA



**Kimberly Scarsi**  
PharmD, MS

University of Nebraska, USA



**Marco Siccardi**  
PhD

University of Liverpool,  
United Kingdom



**Alice Tseng**  
PharmD

Toronto General Hospital,  
Canada

## ABOUT THE WORKSHOP

Understanding the clinical pharmacology of antiviral therapy is pivotal to designing optimal treatment and prevention strategies. Drug exposure is significantly influenced by drug interactions, medication taking behavior, and patients' physiologic and genetic characteristics. These factors are central to determining therapeutic efficacy, failure or toxicity. Despite great progress, many pharmacological challenges still exist.

The International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2021 will again provide a platform for discussions of current topics fundamental to the optimal use of

antiviral therapy including drug-drug interactions, pharmacokinetics of investigational agents and existing drugs, pharmacodynamics, drug dosing in special populations, postmarketing surveillance, and regulatory considerations.

Participants of this workshop will be able to incorporate the new information into clinical guidance for improved disease management of their patients. The knowledge on drug efficacy/toxicity and potential drug interactions will enable clinicians to better manage treatment related complications and, thereby, further optimize antiviral treatment and prevention.

### Program topics:

- Clinical Pharmacology of COVID-19
- Innovative Approaches for Antiviral Pharmacology
- Long-acting Antivirals
- Pharmacological Considerations for Special Populations
- Contribution of Pharmacology to HIV Cure

# CALL FOR ABSTRACTS

We invite all clinicians, pharmacists, and researchers to join the world's leading experts and contribute to the scientific program by submitting an abstract.

## **Abstract submission deadline: 18 June 2021**

Submit now to participate in the discussion on current pharmacological topics fundamental to the optimal use of antiviral therapy.

### **Monday, 20 September 2021**

10:00AM EDT – 2:00 PM EDT

#### **Session 1**

- John Gerber Memorial Lecture
- Transporters Expression in Brain and Other Tissues
- Transporter Probes DDI

#### **Session 2: Clinical Pharmacology of COVID-19**

- Small Molecules and Monoclonal Antibodies Active Against SARS-CoV-2
- Tackling (or Targeting) the Immune System in Patients With COVID-19
- Pharmacological Management of Complex Patients

#### **Abstract-driven Presentations**

### **Tuesday, 21 September 2021**

10:00AM EDT – 1:45 PM EDT

#### **Session 3: Innovative Approaches for Antiviral Pharmacology**

- Predictive Modelling for Drug Development and Clinical Scenarios
- Imaging and LC-MS for Tissue PK

#### **Debate: TAF versus TDF**

#### **Session 4: Long-Active Antivirals**

- Need for an Oral Lead-In and Missed Doses
- Special Populations Including End Organ Failure
- DDIs
- Live Panel Discussion

### **Wednesday, 22 September 2021**

10:00AM EDT – 1:45 PM EDT

#### **Session 5: Pharmacological Considerations for Special Populations**

- PrEP Benchmarks – Can They Cover All Populations – Pregnancy?
- Immune Checkpoint Inhibitors in the Treatment of Hepatitis B
- Pharmacological Focus (Transgender)

#### **Abstract-driven Presentations**

#### **Charles Boucher Memorial Lecture: Contribution of Pharmacology to HIV Cure**

#### **Abstract submission topics:**

- Drug-Drug Interactions
- Novel Drugs and Formulations
- Other Viruses
- Pharmacogenetics
- Pharmacokinetics During Pregnancy
- Pharmacokinetics for Different Patients Populations
- PK/PD Modeling
- PK-PD of Drug Efficacy and Toxicity
- Therapeutic Drug Monitoring
- Cellular and Tissue Pharmacokinetics

#### **SPONSORS**

##### **Platinum level**



##### **Silver level**



##### **Supporter**



##### **Friend**



##### **Endorsers**

